AAAAAA

   
Results: 1-25 | 26-30
Results: 1-25/30
EFFECT OF TROGLITAZONE ON STEADY-STATE PHARMACOKINETICS OF DIGOXIN
Authors: LOI CM KNOWLTON PW STERN R RANDINITIS EJ VASSOS AB KOUP JR SEDMAN AJ
Citation: Cm. Loi et al., EFFECT OF TROGLITAZONE ON STEADY-STATE PHARMACOKINETICS OF DIGOXIN, Journal of clinical pharmacology, 38(2), 1998, pp. 178-183
GABAPENTIN DOES NOT INTERACT WITH A CONTRACEPTIVE REGIMEN OF NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL
Authors: ELDON MA UNDERWOOD BA RANDINITIS EJ SEDMAN AJ
Citation: Ma. Eldon et al., GABAPENTIN DOES NOT INTERACT WITH A CONTRACEPTIVE REGIMEN OF NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, Neurology, 50(4), 1998, pp. 1146-1148
EFFECT OF TROGLITAZONE ON TERFENADINE PHARMACOKINETICS WHEN DOSED 4-HOURS APART
Authors: LOI CM KNOWLTON P STERN R KOUP JR VASSOS AB SEDMAN AJ
Citation: Cm. Loi et al., EFFECT OF TROGLITAZONE ON TERFENADINE PHARMACOKINETICS WHEN DOSED 4-HOURS APART, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 88-88
PHARMACOKINETICS OF PIRMENOL ENANTIOMERS AND PHARMACODYNAMICS OF PIRMENOL RACEMATE IN PATIENTS WITH PREMATURE VENTRICULAR CONTRACTIONS
Authors: JANICZEK N SMITH DE CHANG T SEDMAN AJ STRINGER KA
Citation: N. Janiczek et al., PHARMACOKINETICS OF PIRMENOL ENANTIOMERS AND PHARMACODYNAMICS OF PIRMENOL RACEMATE IN PATIENTS WITH PREMATURE VENTRICULAR CONTRACTIONS, Journal of clinical pharmacology, 37(6), 1997, pp. 502-513
LACK OF EFFECT OF TYPE-II DIABETES ON THE PHARMACOKINETICS OF TROGLITAZONE IN A MULTIPLE-DOSE STUDY
Authors: LOI CM RANDINITIS EJ VASSOS AB KAZIERAD DJ KOUP JR SEDMAN AJ
Citation: Cm. Loi et al., LACK OF EFFECT OF TYPE-II DIABETES ON THE PHARMACOKINETICS OF TROGLITAZONE IN A MULTIPLE-DOSE STUDY, Journal of clinical pharmacology, 37(12), 1997, pp. 1114-1120
SAFETY, TOLERANCE, AND PHARMACODYNAMICS OF CL-1007, A NEW DOPAMINE AUTORECEPTOR AGONIST, IN HEALTHY-SUBJECTS
Authors: ELDON MA UNDERWOOD BA POSVAR EL FENG R WRIGHT DS SEDMAN AJ
Citation: Ma. Eldon et al., SAFETY, TOLERANCE, AND PHARMACODYNAMICS OF CL-1007, A NEW DOPAMINE AUTORECEPTOR AGONIST, IN HEALTHY-SUBJECTS, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 44-44
EXPERIMENTAL EVALUATION OF A RIG TO SIMULATE THE RESPONSE OF THE THORAX TO BLAST LOADING
Authors: COOPER GJ PEARCE BP SEDMAN AJ BUSH IS OAKLEY CW
Citation: Gj. Cooper et al., EXPERIMENTAL EVALUATION OF A RIG TO SIMULATE THE RESPONSE OF THE THORAX TO BLAST LOADING, The journal of trauma, injury, infection, and critical care, 40(3), 1996, pp. 38-41
CHARACTERIZATION OF A 7 DAY 17-BETA-ESTRADIOL TRANSDERMAL DELIVERY SYSTEM - PHARMACOKINETICS IN HEALTHY POSTMENOPAUSAL WOMEN
Authors: BOYD RA ZEGARAC EA ELDON MA SEDMAN AJ FORGUE ST
Citation: Ra. Boyd et al., CHARACTERIZATION OF A 7 DAY 17-BETA-ESTRADIOL TRANSDERMAL DELIVERY SYSTEM - PHARMACOKINETICS IN HEALTHY POSTMENOPAUSAL WOMEN, Biopharmaceutics & drug disposition, 17(6), 1996, pp. 459-470
TOLERANCE AND PHARMACOKINETICS OF SINGLE-DOSE ATORVASTATIN, A POTENT INHIBITOR OF HMG-COA REDUCTASE, IN HEALTHY-SUBJECTS
Authors: POSVAR EL RADULOVIC LL CILLA DD WHITFIELD LR SEDMAN AJ
Citation: El. Posvar et al., TOLERANCE AND PHARMACOKINETICS OF SINGLE-DOSE ATORVASTATIN, A POTENT INHIBITOR OF HMG-COA REDUCTASE, IN HEALTHY-SUBJECTS, Journal of clinical pharmacology, 36(8), 1996, pp. 728-731
PHARMACODYNAMIC EFFECTS AND PHARMACOKINETICS OF ATORVASTATIN AFTER ADMINISTRATION TO NORMOCHOLESTEROLEMIC SUBJECTS IN THE MORNING AND EVENING
Authors: CILLA DD GIBSON DM WHITFIELD LY SEDMAN AJ
Citation: Dd. Cilla et al., PHARMACODYNAMIC EFFECTS AND PHARMACOKINETICS OF ATORVASTATIN AFTER ADMINISTRATION TO NORMOCHOLESTEROLEMIC SUBJECTS IN THE MORNING AND EVENING, Journal of clinical pharmacology, 36(7), 1996, pp. 604-609
EFFECTS OF ATORVASTATIN, AN HMG-COA REDUCTASE INHIBITOR, ON HEPATIC OXIDATIVE-METABOLISM OF ANTIPYRINE
Authors: YANG BB HOUNSLOW NJ SEDMAN AJ FORGUE ST
Citation: Bb. Yang et al., EFFECTS OF ATORVASTATIN, AN HMG-COA REDUCTASE INHIBITOR, ON HEPATIC OXIDATIVE-METABOLISM OF ANTIPYRINE, Journal of clinical pharmacology, 36(4), 1996, pp. 356-360
EFFECT OF AGE AND GENDER ON PHARMACOKINETICS OF ATORVASTATIN IN HUMANS
Authors: GIBSON DM BRON NJ RICHENS A HOUNSLOW NJ SEDMAN AJ WHITFIELD LR
Citation: Dm. Gibson et al., EFFECT OF AGE AND GENDER ON PHARMACOKINETICS OF ATORVASTATIN IN HUMANS, Journal of clinical pharmacology, 36(3), 1996, pp. 242-246
PHARMACOKINETICS OF A 7-DAY 17-BETA-ESTRADIOL TRANSDERMAL DELIVERY SYSTEM - EFFECT OF APPLICATION SITE AND REPEATED APPLICATIONS ON SERUM CONCENTRATIONS OF ESTRADIOL AND ESTRONE
Authors: BOYD RA YANG BB ABEL RB ELDON MA SEDMAN AJ FORGUE ST
Citation: Ra. Boyd et al., PHARMACOKINETICS OF A 7-DAY 17-BETA-ESTRADIOL TRANSDERMAL DELIVERY SYSTEM - EFFECT OF APPLICATION SITE AND REPEATED APPLICATIONS ON SERUM CONCENTRATIONS OF ESTRADIOL AND ESTRONE, Journal of clinical pharmacology, 36(11), 1996, pp. 998-1005
MULTIPLE-DOSE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF ATORVASTATIN, AN INHIBITOR OF HMG-COA REDUCTASE, IN HEALTHY-SUBJECTS
Authors: CILLA DD WHITFIELD LR GIBSON DM SEDMAN AJ POSVAR EL
Citation: Dd. Cilla et al., MULTIPLE-DOSE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF ATORVASTATIN, AN INHIBITOR OF HMG-COA REDUCTASE, IN HEALTHY-SUBJECTS, Clinical pharmacology and therapeutics, 60(6), 1996, pp. 687-695
INHIBITION OF TACRINE ORAL CLEARANCE BY CIMETIDINE
Authors: FORGUE ST REECE PA SEDMAN AJ DEVRIES TM
Citation: St. Forgue et al., INHIBITION OF TACRINE ORAL CLEARANCE BY CIMETIDINE, Clinical pharmacology and therapeutics, 59(4), 1996, pp. 444-449
DISPOSITION OF GABAPENTIN IN ANURIC SUBJECTS ON HEMODIALYSIS
Authors: WONG MO ELDON MA KEANE WF TURCK D BOCKBRADER HN UNDERWOOD BA SEDMAN AJ HALSTENSON CE
Citation: Mo. Wong et al., DISPOSITION OF GABAPENTIN IN ANURIC SUBJECTS ON HEMODIALYSIS, Journal of clinical pharmacology, 35(6), 1995, pp. 622-626
LACK OF EFFECT OF TACRINE ADMINISTRATION ON THE ANTICOAGULANT ACTIVITY OF WARFARIN
Authors: REECE PA GARNETT WR ROCK WL TAYLOR JR UNDERWOOD B SEDMAN AJ RAJAGOPALAN R
Citation: Pa. Reece et al., LACK OF EFFECT OF TACRINE ADMINISTRATION ON THE ANTICOAGULANT ACTIVITY OF WARFARIN, Journal of clinical pharmacology, 35(5), 1995, pp. 526-528
EFFECT OF FOOD ON THE BIOAVAILABILITY OF ATORVASTATIN, AN HMG-COA REDUCTASE INHIBITOR
Authors: RADULOVIC LL CILLA DD POSVAR EL SEDMAN AJ WHITFIELD LR
Citation: Ll. Radulovic et al., EFFECT OF FOOD ON THE BIOAVAILABILITY OF ATORVASTATIN, AN HMG-COA REDUCTASE INHIBITOR, Journal of clinical pharmacology, 35(10), 1995, pp. 990-994
SAFETY AND TOLERABILITY OF CI-979 IN PATIENTS WITH ALZHEIMERS-DISEASE
Authors: SRAMEK JJ SEDMAN AJ REECE PA HOURANI J BOCKBRADER H CUTLER NR
Citation: Jj. Sramek et al., SAFETY AND TOLERABILITY OF CI-979 IN PATIENTS WITH ALZHEIMERS-DISEASE, Life sciences, 57(5), 1995, pp. 503-510
PRECLINICAL AND PHASE-1 CLINICAL CHARACTERIZATION OF CI-979 RU35926, A NOVEL MUSCARINIC AGONIST FOR THE TREATMENT OF ALZHEIMERS-DISEASE/
Authors: SEDMAN AJ BOCKBRADER H SCHWARZ RD
Citation: Aj. Sedman et al., PRECLINICAL AND PHASE-1 CLINICAL CHARACTERIZATION OF CI-979 RU35926, A NOVEL MUSCARINIC AGONIST FOR THE TREATMENT OF ALZHEIMERS-DISEASE/, Life sciences, 56(11-12), 1995, pp. 877-882
AN EXAMINATION OF THE MICROMECHANICS OF FAILURE OF BONE AND ANTLER BYACOUSTIC-EMISSION TESTS AND LASER-SCANNING-CONFOCAL-MICROSCOPY
Authors: ZIOUPOS P CURREY JD SEDMAN AJ
Citation: P. Zioupos et al., AN EXAMINATION OF THE MICROMECHANICS OF FAILURE OF BONE AND ANTLER BYACOUSTIC-EMISSION TESTS AND LASER-SCANNING-CONFOCAL-MICROSCOPY, Medical engineering & physics, 16(3), 1994, pp. 203-212
THE PHARMACOKINETICS OF QUINAPRIL AND QUINAPRILAT IN PATIENTS WITH CONGESTIVE-HEART-FAILURE
Authors: BEGG EJ ROBSON RA IKRAM H RICHARDS AM BAMMERTADAMS JA OLSON SC POSVAR EL REECE PA SEDMAN AJ
Citation: Ej. Begg et al., THE PHARMACOKINETICS OF QUINAPRIL AND QUINAPRILAT IN PATIENTS WITH CONGESTIVE-HEART-FAILURE, British journal of clinical pharmacology, 37(3), 1994, pp. 302-304
DIURETIC EFFECTS, PHARMACOKINETICS, AND SAFETY OF A NEW CENTRALLY ACTING KAPPA-OPIOID AGONIST (CI-977) IN HUMANS
Authors: REECE PA SEDMAN AJ ROSE S WRIGHT DS DAWKINS R RAJAGOPALAN R
Citation: Pa. Reece et al., DIURETIC EFFECTS, PHARMACOKINETICS, AND SAFETY OF A NEW CENTRALLY ACTING KAPPA-OPIOID AGONIST (CI-977) IN HUMANS, Journal of clinical pharmacology, 34(11), 1994, pp. 1126-1132
THE TEMPORAL EFFECT OF FOOD ON TACRINE BIOAVAILABILITY
Authors: WELTY DF SIEDLIK PH POSVAR EL SELEN A SEDMAN AJ
Citation: Df. Welty et al., THE TEMPORAL EFFECT OF FOOD ON TACRINE BIOAVAILABILITY, Journal of clinical pharmacology, 34(10), 1994, pp. 985-988
LACK OF INTERACTION OF GABAPENTIN WITH CARBAMAZEPINE OR VALPROATE (VOL 35, PG 155, 1994)
Authors: RADULOVIC LL WILDER BJ LEPPIK IE BOCKBRADER HN CHANG T POSVAR EL SEDMAN AJ UTHMAN BM ERDMAN GR
Citation: Ll. Radulovic et al., LACK OF INTERACTION OF GABAPENTIN WITH CARBAMAZEPINE OR VALPROATE (VOL 35, PG 155, 1994), Epilepsia, 35(3), 1994, pp. 707-707
Risultati: 1-25 | 26-30